IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Letterio, J. J.
Right arrow Articles by Chanock, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Letterio, J. J.
Right arrow Articles by Chanock, S. J.

 Previous Article  |  Next Article 

Infection and Immunity, August 2001, p. 5115-5120, Vol. 69, No. 8
0019-9567/01/$04.00+0   DOI: 10.1128/IAI.69.8.5115-5120.2001

Invasive Candidiasis Stimulates Hepatocyte and Monocyte Production of Active Transforming Growth Factor beta

John J. Letterio,1 Thomas Lehrnbecher,2,3 Greg Pollack,1 Thomas J. Walsh,2 and Stephen J. Chanock2,3,*

Laboratory of Cell Regulation and Carcinogenesis,1 Immunocompromised Host Section, Pediatric Oncology Branch,2 and Advanced Technology Center,3 National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

Received 30 November 2000/Returned for modification 6 February 2001/Accepted 17 April 2001


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Candida albicans is an opportunistic fungal pathogen and a major cause of morbidity and mortality in patients with compromised immune function. The cytokine response to tissue invasion by C. albicans can influence the differentiation and function of lymphocytes and other mononuclear cells that are critical components of the host response. While the production of transforming growth factor beta  (TGF-beta ) has been documented in mice infected with C. albicans and is known to suppress phagocyte function, the cellular source and role of this cytokine in the pathogenesis of systemic candidiasis are not well understood. We have investigated the source of production of TGF-beta by immunohistochemical studies in tissue samples from patients with an uncommon complication of lymphoreticular malignancy, chronic disseminated candidiasis (CDC), and from a neutropenic-rabbit model of CDC. Liver biopsy specimens from patients with documented CDC demonstrated intense staining for extracellular matrix-associated TGF-beta 1 within inflammatory granulomas, as well as staining for TGF-beta 1 and TGF-beta 3 within adjacent hepatocytes. These results correlate with the immunolocalization of TGF-beta observed in livers of infected neutropenic rabbits, using a neutralizing antibody that recognizes the mature TGF-beta protein. Human peripheral blood monocytes incubated with C. albicans in vitro release large amounts of biologically active TGF-beta 1. The data demonstrate that local production of active TGF-beta s by hepatocytes and by infected mononuclear cells is a component of the response to C. albicans infection that most probably contributes to disease progression in the immunocompromised host.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Chronic disseminated candidiasis (CDC) is a serious infectious complication that occurs in patients suffering prolonged periods of neutropenia (25). Successful treatment of CDC typically requires protracted courses of antifungal therapy (56). Parenchymal lesions within the liver in which yeast and pseudohyphae can be found become apparent during recovery from neutropenia and can progress in size, often with a strong local inflammatory response. This observation suggests that inhibitory factors produced locally in response to fungal infection could impair an effective immune response and consequently, as circulating neutrophils and monocytes recover, contribute to the pathogenesis and prognosis of CDC. Several aspects of the host response to Candida albicans have been defined through studies of humans with CDC and animal models of disseminated infection. A suitable animal model for C. albicans infection of the liver in neutropenic rabbits provides an excellent opportunity to investigate the pathophysiological model and to develop new therapeutic strategies (54, 55).

An effective phagocytic response absolutely depends on a balance between pro-and anti-inflammatory cytokines and on T-helper cells. Studies of animals models of C. albicans infection have illustrated the protective role of T-helper lymphocyte type 1 (Th1) cytokines and the suppressive effect of Th2 cytokines on the host response to infection (34, 42). For example, interleukin-12 (IL-12) is required for Th1 differentiation in murine candidiasis (40), and production of this cytokine by neutrophils correlates with a protective response (41). Exogenous IL-12 is effective in protecting neutropenic hosts susceptible to infection and can enhance the host phagocytic response to C. albicans (41). The role of Th2 cytokines is less clearly defined, but current data suggest that they impair the host response to C. albicans (10, 29, 35, 49). Measurement of high circulating levels of IL-10 in patients with CDC (38) indicates a shift toward the Th2 response. IL-10 is a potent inhibitor of cytokine synthesis in human monocytes (15) and can inhibit the release of proinflammatory cytokines, such as IL-1 and tumor necrosis factor alpha (8, 9). IL-10 inhibits the phagocytic activity of human neutrophils (7) and suppresses antifungal activities of human monocytes against the pseudohyphae and blastoconidida of C. albicans (36).

Transforming growth factor beta  (TGF-beta ) is another important inhibitory cytokine (5, 27), but the role that it plays during infection with C. albicans is not clearly defined. Release of TGF-beta down-regulates activated monocytes and macrophages, suppressing gamma interferon (IFN-gamma )-induced production of nitric oxide (51), which would favor the dissemination and progression of C. albicans infection. TGF-beta is generally thought to influence the differentiation of naive CD4+T cells toward the Th2 profile (27), although it has been shown to inhibit Th2 differentiation (21). Murine models characterized by disruptions in the TGF-beta pathway are notable for a proinflammatory phenotype, with spontaneous differentiation and activation of T cells producing IFN-gamma and IL-4 (20, 26, 46). Studies with mice have suggested a role for TGF-beta in determining the response to C. albicans (48), by demonstrating that production of TGF-beta quickly follows infection with a nonvirulent vaccine strain of C. albicans, and have shown that this role might be important in the development of resistance. However, the observation that administration of exogenous TGF-beta could promote the development of a Th1 response in these mice highlights the complex local effects of this cytokine and suggests that TGF-beta might play a critical regulatory role in the host response to C. albicans infection (48).

Although these studies have shown that systemic administration of a neutralizing anti-TGF-beta antibody can affect the course of C. albicans infection in mice, the cellular source and local production of TGF-beta have not been clearly determined. The objective of this study was to demonstrate that local production of TGF-beta accompanies the granulomatous response to tissue invasion in CDC and to investigate whether human monocytes challenged by C. albicans produce biologically active TGF-beta . The results suggest an important role for TGF-beta in the pathophysiology of CDC.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Human liver biopsy specimens. Seven patients with biopsy-documented CDC were identified, and 5-µm sections were prepared from archival specimens that had previously been fixed in formalin and embedded in paraffin. Specimens were processed for immunohistochemical analysis of TGF-beta as described below.

Rabbit model of CDC. New Zealand White rabbits (weight, 2.5 to 3.5 kg; Hazleton, Denver, Pa.) were used for all experiments and were given water and standard rabbit feed ad libitum according to National Institutes of Health guidelines (12). The immunosuppressive regimen and supportive care measures were as previously described (54, 55). Briefly, cytosine arabinoside (Upjohn Pharmaceuticals, Kalamazoo, Mich.) was administered intravenously at 440 mg/m2 on days 1 through 5 and on days 8 to 9 and days 13 to 14 to produce profound and persistent neutropenia, respectively, and starting on day 4, rabbits received intravenous administration of ceftazidime (Glaxo Pharmaceuticals, Research Triangle Park, N.C.) at 75 mg/kg, twice daily, gentamicin (Baxter Health Care Corp., Deerfield, Ill.) at 5 mg/kg every other day, and vancomycin (Eli Lilly & Co., Indianapolis, Ind.) intravenously at 15 mg/kg daily to prevent the occurrence of invasive bacterial infections during neutropenia. An inoculum of 103 CFU of C. albicans was administered on day 6 as previously described (22).

Immunohistochemical detection of TGF-beta isoforms in human and rabbit tissues. Sections 5 µm thick were stained with hematoxylin and eosin for routine histological evaluation. Additional sections were evaluated with isoform-specific anti-TGF-beta antibodies directed against TGF-beta 1 (18), TGF-beta 2 (16), and TGF-beta 3 (17), followed by peroxidase staining as previously described (18). The sections were also evaluated using a biotinylated mouse monoclonal antibody that was raised against mature, active TGF-beta 2 but can recognize and neutralize the activity of all three isoforms (clone 1D11; Genzyme, Cambridge, Mass., and now available through R&D Systems, Minneapolis, Minn.).

Monocyte infection and preparation of conditioned media. Peripheral blood monocytes were isolated by a two-step procedure, automated leukopheresis followed by counterflow elutriation (model J-6M centrifuge; Beckman Instruments, Fullerton, Calif.) (53). Cell viability was determined to be >95% by trypan blue exclusion. Morphological analysis by using modified Wright-Giemsa stain and nonspecific esterase stain confirmed that >95% of the isolated cells were monocytes. In preparation for ex vivo studies, monocytes were washed twice in RPMI without fetal calf serum and kept on ice throughout preparation. The monocytes were resuspended in RPMI at 106/ml in a total volume of 30 ml, immediately placed in a 5% CO2 water incubator, and subjected to either C. albicans strain 86-21 challenge or a sterile-water control treatment. The C. albicans strain is a clinical specimen and has been previously studied (37). Monocyte suspensions were challenged with C. albicans at a multiplicity of infection (MOI [target-to-effector cells]) of 10:1, 1:1, and 1:10 in duplicate. Supernatants were collected at 8, 12, 24, and 48 h after initial infection. The viability of cells was assessed by trypan blue stain exclusion. For the time points collected, the viability of monocytes exposed to an MOI of 10:1 was less than 50%. For the other conditions, the viability was >95% at the time of collection. Supernatants were collected and frozen at -70°C until analysis.

TGF-beta bioassay. A modified Mv1Lu bioassay was used (13). Cells were plated at 2 × 105 cells per well in 24-well plates with 1 ml of Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and incubated for 8 to 12 h at 37°C to ensure complete adherence. The medium was aspirated and replaced with serial dilutions of each conditioned medium (diluted in Dulbecco's modified Eagle's medium containing 0.2% fetal bovine serum) in the presence or absence of 30 µg of either the panspecific mouse monoclonal anti-TGF-beta blocking antibody 1D11 or control IgG per ml; additional wells were treated with medium plus TGF-beta standard concentrations in a total volume of 500 µl/well (each condition was tested in triplicate). The plates were subsequently incubated for an additional 24 h, and 1 mCi of [3H]thymidine was added for the final 2 h of the incubation. The medium was aspirated and replaced with 50 µl of trypsin-EDTA/well, and the cells were incubated for 30 min at 37°C before being harvested onto 24-well filter plates, which were processed with a Top Count microplate scintillation reader as specified by the manufacturer (Packard Instrument Co., Meriden, Conn.).

TGF-beta SELISA. Culture supernatants were collected as above for determination of total TGF-beta by the Quantikine SELISA (R&D Systems). Total TGF-beta was measured after acidification to activate latent TGF-beta followed by neutralization specified by the manufacturer, with standard curves for TGF-beta generated with known amounts of purified recombinant human TGF-beta 1.


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Production of TGF-beta accompanies the local inflammatory response to C. albicans in vivo. We examined the expression of TGF-beta within the inflammatory liver granulomas of seven patients with documented CDC. Immunohistochemical studies demonstrated intense staining for TGF-beta 1 within the extracellular matrix surrounding infiltrates of leukocytes within the liver parenchyma (Fig. 1A to D) and revealed an extensive accumulation of TGF-beta protein encasing necrotic foci that resulted from the intense local inflammatory reaction (Fig. 1E).


View larger version (129K):
[in this window]
[in a new window]
 
FIG. 1.   Immunolocalization of TGF-beta 1 within the extracellular matrix of hepatic granulomas of patients with CDC. Tissue sections from seven patients with CDC were examined by immunohistochemistry with a polyclonal rabbit antibody (designated CC) that detects extracellular, matrix-associated TGF-beta 1. Sections stained with normal rabbit serum (A) or the CC antibody (B to E) are shown.

We also examined the hepatocyte expression of the different TGF-beta isoforms in areas adjacent to the inflammatory reaction. There was strong cytoplasmic localization of both TGF-beta 3 (Fig. 2B), and TGF-beta 1 (Fig. 2C and D) to hepatocytes in all biopsy specimens, with the predominant expression centered around sites of inflammation. We subsequently evaluated whether this local expression of TGF-beta detected in livers of immunocompromised patients might also be a feature of the invasive lesions observed in the neutropenic-rabbit model of CDC. Similar to the findings in human liver biopsy specimens, an accumulation of extracellular TGF-beta 1 was evident in rabbit liver sections that were stained with an antibody reactive to matrix-associated forms of the mature protein (Fig. 3A to D). We also used a biotinylated anti-TGF-beta mouse IgG that is not isoform specific but does recognize the mature, active forms of TGF-beta . Once again, we observed intense cytoplasmic staining for TGF-beta within hepatocytes in regions of the liver where inflammation was most abundant (Fig. 3E and F).


View larger version (159K):
[in this window]
[in a new window]
 
FIG. 2.   Immunolocalization of TGF-beta 1 and TGF-beta 3 in hepatocytes adjacent to inflammatory granulomas. Tissue sections from patients with CDC were examined by immunohistochemistry with either normal rabbit serum (A) or polyclonal rabbit antibodies to TGF-beta 3 (B and C), or TGF-beta 1 (D). Results are representative of staining patterns observed in all sections examined.


View larger version (180K):
[in this window]
[in a new window]
 
FIG. 3.   Immunolocalization of TGF-beta in sections of liver taken from neutropenic rabbits infected with C. albicans. (A to D) Sections were preblocked with normal goat serum prior to incubation with the rabbit polycolonal CC antibody directed against extracellular TGF-beta 1 (A and C) and compared with control staining with normal rabbit serum (B and D). (E and F) The murine monoclonal panspecific anti-TGF-beta antibody 1D11 was biotinylated and used to detect intracellular, active TGF-beta within hepatocytes of C. albicans-infected livers (E) and compared to staining with normal mouse serum (F).

Monocyte infection by C. albicans results in the secretion of biologically active TGF-beta . Infiltrating leukocytes might also contribute to the local production of TGF-beta in the liver following infection with C. albicans. To study this possibility, monocytes were isolated by leukapheresis and counterflow elutriation and cultured at specified ratios of blastoconidia to monocytes in serum-free medium. Culture supernatants were then collected at time intervals ranging from 8 to 48 h, and the presence of biologically active TGF-beta was determined by the ability to inhibit growth of a TGF-beta -sensitive mink lung epithelial cell line in a manner reversible with a neutralizing. TGF-beta -specific antibody. Supernatants from cultures of 1.5 × 106/ml monocytes at a blastoconidia-to-monocyte ratio of 1:1 contained more than 1 ng of biologically active TGF-beta per ml. As shown in Fig. 4, substantial amounts of TGF-beta could be detected as early as 12 h, and similar results were obtained in assays of supernatants collected at later time points. A determination of total TGF-beta was performed on the same culture supernatants following a transient acidification to release any mature TGF-beta remaining associated with the latency-associated protein. The results shown in Fig. 5 directly correlate with values determined by the bioassay and suggest that the majority of the TGF-beta released into the medium by infected monocytes is biologically active.


View larger version (24K):
[in this window]
[in a new window]
 
FIG. 4.   Production of active TGF-beta by C. albicans infected human peripheral blood monocytes. Peripheral blood monocytes were collected as described in Materials and Methods and cultured in defined medium with blastoconidia for the indicated time intervals. (A) The medium was collected and assayed for the presence of TGF-beta , and the result was compared to a standard curve generated by the response to recombinant human TGF-beta 1 (B and C) The conditioned medium samples collected at 12 h (B) and 24 h (C) each contained an activity capable of inhibiting the proliferation of Mv1lu cells (black bars) in a manner reversible by a TGF-beta neutralizing antibody (white bar) but not by a nonneutralizing, isotype control IgG (hatched bar), thereby demonstrating TGF-beta - specificity of the neutralization of growth inhibition. Levels of TGF-beta were most notable at target-to-effector-cell (T:E) (yeast/monocyte) ratios of 10:1 and 1:1. The results in panels B and C are the mean of three separate experiments for conditioned medium at a 1:2 dilution.


View larger version (25K):
[in this window]
[in a new window]
 
FIG. 5.   Production of active TGF-beta by C. albicans-infected human peripheral blood monocytes. In addition to a bioassay of conditioned medium, we performed a SELISA for TGF-beta 1 as described in Materials and Methods. The results for acid-activated conditioned medium at a 1:2 dilution directly correlate with the level of activity as determined by the inhibition of Mv1lu cell growth. These results suggest that the majority of the TGF-beta secreted by Candida-infected monocytes has been processed to a biologically active form. Ratios of yeast to monocytes (T:E) were as indicated and were obtained with the same culture supernatants used for experiments in Fig. 4.


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Our results demonstrate that active TGF-beta is produced by hepatocytes and infiltrating monocytes within inflammatory granulomas during CDC. Furthermore, we show an induction of active TGF-beta in hepatocytes and an accumulation of extracellular, matrix-associated TGF-beta in areas surrounding both inflammatory granulomas and the residual necrotic foci that are characteristic of CDC. We present evidence that local production of TGF-beta is not unique to CDC in humans but that it also occurs during C. albicans infection in immunocompromised rabbits following prolonged periods of neutropenia. Infection of monocytes with C. albicans leads to the secretion of active TGF-beta , clearly implicating leukocytes as an additional source of this cytokine in CDC. Since clinical expression of CDC is often accelerated during and after recovery from neutropenia and monocytopenia, we infer that the high local concentration of TGF-beta participates in the suppression of host defenses.

Previously, it has been shown that the immunoregulatory properties of TGF-beta affect the differentiation and function of nearly every leukocyte subset (27). TGF-beta primarily inhibits the differentiated function of immune cells (i.e., phagocytes), although several studies suggest that it can also enhance the function of lymphocytes and macrophages. For example, femtomolar concentrations of TGF-beta are chemotactic for human peripheral blood monocytes and neutrophils, suggesting a critical role in recruitment to sites of injury or inflammation. Mice lacking the MADH3 gene, encoding the TGF-beta receptor-activated Smad3, have defective chemotactic responses to TGF-beta in neutrophils, monocytes, and keratinocytes; they spontaneously develop mucosal abscesses with nonpathogenic Providencia spp. (14, 59). TGF-beta can also contribute to the formation of inflammatory foci by enhancing the expression of several integrin receptors on monocytes, namely, LFA-1, VLA-3, and VLA-5 (3, 52). TGF-beta enhances phagocytosis by induction of the expression of Fcgamma RIII receptors on circulating monocytes (57). These data suggest that local production of TGF-beta within tissues may promote the infiltration of mononuclear cells responding to pathogens such as C. albicans.

On the other hand, TGF-beta is also known to inhibit the function of immune cells (i.e., lymphocytes and phagocytes) postactivation. For example, TGF-beta is a potent inhibitor of the production of reactive oxygen radicals and nitrogen intermediates by cells activated by either IFN-gamma or bacterial lipopolysaccharide. (6, 51). Interestingly these activating signals are also recognized for their ability to induce monocytes and macrophages to release TGF-beta in an active state, through mechanisms that involve the serine protease plasmin and tissue type II transglutaminase (32, 33). C. albicans infection of IFN-gamma and lipopolysaccharide-activated murine peritoneal macrophages can also suppress the production of nitric oxide, although this effect has been described as being independent of induction by TGF-beta , primarily because it was not neutralized by a blocking antibody to TGF-beta (11). While this autocrine activity generally is believed to function as an important feedback-inhibitory mechanism for limiting the extent and duration of an inflammatory response, it is also well recognized as a microbial escape mechanism in human and murine forms of parasitic infection. Indeed, infection of host macrophages with either Leishmania or the protozoan parasite Trypanosoma cruzi results in the secretion of the mature, active TGF-beta that suppresses microbicidal activity against the parasite and thereby enhances the proliferation of the pathogen (1, 2, 30, 47). The effects of TGF-beta on the development of host defense pathways have also been studied during infection with Mycobacterium tuberculosis and leprosy. TGF-beta is produced by M. tuberculosis-infected macrophages (39), and neutralization of TGF-beta normalizes lymphocyte proliferative responses to the standard purified protein derivative; partially restores blastogenesis to candidal antigen, and increases IFN-gamma production, indicating that TGF-beta is an important mediator of immunosuppression in tuberculosis (23, 24). In leprosy, two different patterns of TGF-beta isoform expression are seen in the polar forms of leprosy in skin biopsy specimens; in the paucibacillary form, expression of the latent form of TGF-beta 1 was detected, whereas in the tuberculoid form, high levels of the active isoforms were detected (58). Our data provide preliminary evidence that C. albicans could utilize a comparable strategy in the neutropenic host, similar to the observed response to M. tuberculosis and selected parasitic infections. In our CDC study, the active isoform of TGF-beta 1 is highly expressed and could be a contributing factor to CDC pathogenesis.

Another important component of the host response to C. albicans is the development of an effective Th1 response. The contribution of TGF-beta to Th cell differentiation is complex, but early studies suggested that TGF-beta promotes the differentiation of staphylococcal enterotoxin B-stimulated CD4+ T cells toward the Th1 phenotype (31). Conversely, others have demonstrated that TGF-beta inhibits IL-12-induced Th1 development and IFN-gamma production (44, 45). More recent studies involving polyclonal activation of naîve CD4+ T cells and ovalbumin-specific Th cells have demonstrated that a mixture of IL-4 and TGF-beta can promote the development of either Th1 or Th2 cells in a concentration dependent manner (28). However, the induction of a Th1 phenotype was dependent on the presence of IFN-gamma , which has recently been shown to block TGF-beta receptor-mediated signaling though the induction of the inhibitory Smad7 (50).

The establishment of an effective Th1 response in mice with systemic candidiasis is thought to be dependent on several factors, including the production of IL-12 (43) and the early presence of IL-4, which can prime neutrophils for production of IL-12 (29). Studies with mice have shown that IFN-gamma is required for an effective Th1 response to C. albicans but also suggest that presence of TGF-beta could favor a Th1 response (48). Taken together, these observations suggest that multiple pathways contribute to the differentiation of naîve T cells and that the intracellular cross talk between pathways, including TGF-beta and Th1 cytokines (4, 50, 60), could unfavorably tip the balance of the host immune response in the neutropenic host.

The current data collectively demonstrate that TGF-beta is an important determinant of the host response to systemic candidiasis. As a consequence of the suppressive effects of TGF-beta on the phagocytic response, the production of active TGF-beta in immunocompromised patients and rabbits with CDC is an important local event, inhibiting effective cell-mediated immunity while permitting ineffective granuloma formation in response to C. albicans infection. One must therefore consider the complex role of this molecule and, specifically, a role for the beneficial effects of TGF-beta on Th-cell differentiation. Finally, our study provides evidence that TGF-beta production is at least a consequence of C. albicans infection and, indeed, could be a contributing factor to an unusual type of infection in the severely immunocompromised host. Other factors, such as host genetic profiles and prior immunosuppression, certainly have to be considered in a comprehensive understanding of the pathophysiology of CDC (19).


    ACKNOWLEDGMENTS

We thank Anita Roberts for critical review of the manuscript.

T.L. was supported by a Mildred Scheel Stipendium, Deutsche Krebshilfe e.V.


    FOOTNOTES

* Corresponding author. Mailing address: Immunocompromised Host Section, Pediatric Oncology Branch and The Advanced Technology Center, National Cancer Institute, 8717 Grovemont Circle, Gaithersburg, MD 20877. Phone: (301) 435-7559. Fax: (301) 402-3134. E-mail: sc83a{at}nih.gov.

Editor:   T. R. Kozel


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Barral, A., M. Barral-Netto, E. C. Yong, C. E. Brownell, D. R. Twardzik, and S. G. Reed. 1993. Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc. Natl. Acad. Sci. USA 90:3442-3446[Abstract/Free Full Text].
2. Barral-Netto, M., A. Barral, C. E. Brownell, Y. A. Skeiky, L. R. Ellingsworth, D. R. Twardzik, and S. G. Reed. 1992. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257:545-548[Abstract/Free Full Text].
3. Bauvois, B., D. Rouillard, J. Sanceau, and J. Wietzerbin. 1992. IFN-gamma and transforming growth factor-beta 1 differently regulate fibronectin and laminin receptors of human differentiating monocytic cells. J. Immunol. 148:3912-3919[Abstract].
4. Bitzer, M., G. von Gersdorff, D. Liang, A. Dominguez-Rosales, A. A. Beg, M. Rojkind, and E. P. Bottinger. 2000. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev. 14:187-197[Abstract/Free Full Text].
5. Blobe, G. C., W. P. Schiemann, and H. F. Lodish. 2000. Role of transforming growth factor beta in human disease. N. Engl. J. Med. 342:1350-1358[Free Full Text].
6. Bogdan, C., and C. Nathan. 1993. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann. N. Y. Acad. Sci. 685:713-739[Abstract].
7. Cassatella, M. A. 1998. The neutrophil: one of the cellular targets of interleukin-10. Int. J. Clin. Lab. Res. 28:148-161[CrossRef][Medline].
8. Cassatella, M. A., L. Meda, S. Bonora, M. Ceska, and G. Constantin. 1993. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J. Exp. Med. 178:2207-2211[Abstract/Free Full Text].
9. Cassatella, M. A., L. Meda, S. Gasperini, F. Calzetti, and S. Bonora. 1994. Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J. Exp. Med. 179:1695-1699[Abstract/Free Full Text].
10. Cenci, E., L. Romani, A. Mencacci, R. Spaccapelo, E. Schiaffella, P. Puccetti, and F. Bistoni. 1993. Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur. J. Immunol. 23:1034-1038[Medline].
11. Chinen, T., M. H. Qureshi, Y. Koguchi, and K. Kawakami. 1999. Candida albicans suppresses nitric oxide (NO) production by interferon-gamma (IFN-gamma) and lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages. Clin. Exp. Immunol. 115:491-497[CrossRef][Medline].
12. Committe on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission on Life Sciences National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
13. Danielpour, D., L. L. Dart, K. C. Flanders, A. B. Roberts, and M. B. Sporn. 1989. Immunodetection and quantitation of the two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) secreted by cells in culture. J. Cell. Physiol. 138:79-86[CrossRef][Medline].
14. Datto, M. B., J. P. Frederick, L. Pan, A. J. Borton, Y. Zhuang, and X. F. Wang. 1999. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol. Cell. Biol. 19:2495-2504[Abstract/Free Full Text].
15. De Waal Malefyt, R., M., J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries. 1991. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:1209-1220[Abstract/Free Full Text].
16. Flanders, K. C., D. S. Cissel, L. T. Mullen, D. Danielpour, M. B. Sporn, and A. B. Roberts. 1990. Antibodies to transforming growth factor-beta 2 peptides: specific detection of TGF-beta 2 in immunoassays. Growth Factors 3:45-52[Medline].
17. Flanders, K. C., G. Ludecke, S. Engels, D. S. Cissel, A. B. Roberts, P. Kondaiah, R. Lafyatis, M. B. Sporn, and K. Unsicker. 1991. Localization and actions of transforming growth factor-beta s in the embryonic nervous system. Development 113:183-191[Abstract].
18. Flanders, K. C., N. L. Thompson, D. S. Cissel, E. Van Obberghen-Schilling, C. C. Baker, M. E. Kass, L. R. Ellingsworth, A. B. Roberts, and M. B. Sporn. 1989. Transforming growth factor-beta 1: histochemical localization with antibodies to different epitopes. J. Cell Biol. 108:653-660[Abstract/Free Full Text].
19. Foster, C. B., and S. J. Chanock. 2000. Mining variations in genes of innate and phagocytic immunity: current status and future prospects. Curr. Opin. Hematol. 7:9-15[CrossRef][Medline].
20. Gorelik, L., and R. A. Flavell. 2000. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12:171-181[CrossRef][Medline].
21. Gorelik, L., P. E. Fields, and R. A. Flavell. 2000. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J. Immunol. 165:4773-4777[Abstract/Free Full Text].
22. Groll, A. H., V. Petraitis, R. Petraitiene, A. Field-Ridley, M. Calendario, J. Bacher, S. C. Piscitelli, and T. J. Walsh. 1999. Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 43:2463-2467[Abstract/Free Full Text].
23. Hirsch, C. S., J. J. Ellner, R. Blinkhorn, and Z. Toossi. 1997. In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta. Proc. Natl. Acad. Sci. USA 94:3926-3931[Abstract/Free Full Text].
24. Hirsch, C. S., R. Hussain, Z. Toossi, G. Dawood, F. Shahid, and J. J. Ellner. 1996. Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. Proc. Natl. Acad. Sci. USA 93:3193-3198[Abstract/Free Full Text].
25. Kontoyiannis, D. P., M. A. Luna, B. I. Samuels, and G. P. Bodey. 2000. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect. Dis. Clin. North Am. 14:721-739[CrossRef][Medline].
26. Kulkarni, A. B., C. G. Huh, D. Becker, A. Geiser, M. Lyght, K. C. Flanders, A. B. Roberts, M. B. Sporn, J. M. Ward, and S. Karlsson. 1993. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 90:770-774[Abstract/Free Full Text].
27. Letterio, J. J., and A. B. Roberts. 1998. Regulation of immune responses by TGF-beta. Annu. Rev. Immunol. 16:137-161[CrossRef][Medline].
28. Lingnau, K., P. Hoehn, S. Kerdine, S. Koelsch, C. Neudoerfl, N. Palm, E. Ruede, and E. Schmitt. 1998. IL-4 in combination with TGF-beta favors an alternative pathway of Th1 development independent of IL-12. J. Immunol. 161:4709-4718[Abstract/Free Full Text].
29. Mencacci, A., G. Del Sero, E. Cenci, C. F. d'Ostiani, A. Bacci, C. Montagnoli, M. Kopf, and L. Romani. 1998. Endogenous interleukin 4 is required for development of protective CD4+ T helper type 1 cell responses to Candida albicans. J. Exp. Med. 187:307-317[Abstract/Free Full Text].
30. Ming, M., M. E. Ewen, and M. E. Pereira. 1995. Trypanosome invasion of mammalian cells requires activation of the TGF beta signaling pathway. Cell 82:287-296[CrossRef][Medline].
31. Nagelkerken, L., K. J. Gollob, M. Tielemans, and R. L. Coffman. 1993. Role of transforming growth factor-beta in the preferential induction of T helper cells of type 1 by staphylococcal enterotoxin B. Eur. J. Immunol. 23:2306-2310[Medline].
32. Nunes, I., J. S. Munger, J. G. Harpel, Y. Nagano, R. L. Shapiro, P. E. Gleizes, and D. B. Rifkin. 1996. Structure and activation of the large latent transforming growth factor-beta complex. Int. J. Obes. Relat. Metab. Disord. 20(Suppl. 3):S4-S8.
33. Nunes, I., R. L. Shapiro, and D. B. Rifkin. 1995. Characterization of latent TGF-beta activation by murine peritoneal macrophages. J. Immunol. 155:1450-1459[Abstract].
34. Puccetti, P., L. Romani, and F. Bistoni. 1995. A TH1-TH2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol. 3:237-240[CrossRef][Medline].
35. Puccetti, P., A. Mencacci, E. Cenci, R. Spaccapelo, P. Mosci, K. H. Enssle, L. Romani, and F. Bistoni. 1994. Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J. Infect. Dis. 169:1325[Medline].
36. Roilides, E., A. Anastasiou-Katsiardani, A. Dimitriadou-Georgiadou, I. Kadiltsoglou, S. Tsaparidou, C. Panteliadis, and T. J. Walsh. 1998. Suppressive effects of interleukin-10 on human mononuclear phagocyte function against Candida albicans and Staphylococcus aureus. J. Infect. Dis. 178:1734-1742[CrossRef][Medline].
37. Roilides, E., C. A. Lyman, S. D. Mertins, D. J. Cole, D. Venzon, P. A. Pizzo, S. J. Chanock, and T. J. Walsh. 1996. Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens. Cytokine 8:42-48[CrossRef][Medline].
38. Roilides, E., T. Sein, R. Schaufele, S. J. Chanock, and T. J. Walsh. 1998. Increased serum concentrations of interleukin-10 in patients with hepatosplenic candidiasis. J. Infect. Dis. 178:589-592[Medline].
39. Rojas, R. E., K. N. Balaji, A. Subramanian, and W. H. Boom. 1999. Regulation of human CD4(+) alphabeta T-cell-receptor-positive [TCR(+)] and gamma delta TCR(+) T-cell responses to mycobacterium tuberculosis by interleukin-10 and transforming growth factor beta . Infect. Immun. 67:6461-6472[Abstract/Free Full Text].
40. Romani, L., F. Bistoni, A. Mencacci, E. Cenci, R. Spaccapelo, and P. Puccetti. 1995. IL12 in Candida albicans infections. Res. Immunol. 146:532-538[CrossRef][Medline].
41. Romani, L., F. Bistoni, and P. Puccetti. 1997. Initiation of T-helper cell immunity to Candida albicans by IL-12: the role of neutrophils. Chem. Immunol. 68:110-135[Medline].
42. Romani, L., E. Cenci, A. Menacci, F. Bistoni, and P. Puccetti. 1995. T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design. Immunol. Res. 14:148-162[Medline].
43. Romani, L., A. Mencacci, L. Tonnetti, R. Spaccapelo, E. Cenci, S. Wolf, P. Puccetti, and F. Bistoni. 1994. Interleukin-12 but not interferon-gamma production correlates with induction of T helper type-1 phenotype in murine candidiasis. Eur. J. Immunol. 24:909-915[Medline].
44. Schmitt, E., P. Hoehn, C. Huels, S. Goedert, N. Palm, E. Rude, and T. Germann. 1994. T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur. J. Immunol. 24:793-798[Medline].
45. Schmitt, E., E. Rude, and T. Germann. 1997. The immunostimulatory function of IL-12 in T-helper cell development and its regulation by TGF-beta, IFN-gamma and IL-4. Chem. Immunol. 68:70-85[Medline].
46. Shull, M. M., I. Ormsby, A. B. Kier, S. Pawlowski, R. J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin, et al. 1992. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:693-699[CrossRef][Medline].
47. Silva, J. S., D. R. Twardzik, and S. G. Reed. 1991. Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta). J Exp. Med. 174:539-545[Abstract/Free Full Text].
48. Spaccapelo, R., L. Romani, L. Tonnetti, E. Cenci, A. Mencacci, G. Del Sero, R. Tognellini, S. G. Reed, P. Puccetti, and F. Bistoni. 1995. TGF-beta is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans. J. Immunol. 155:1349-1360[Abstract].
49. Tonnetti, L., R. Spaccapelo, E. Cenci, A. Mencacci, P. Puccetti, R. L. Coffman, F. Bistoni, and L. Romani. 1995. Interleukin-4 and -10 exacerbate candidiasis in mice. Eur. J. Immunol. 25:1559-1565[Medline].
50. Ulloa, L., J. Doody, and J. Massague. 1999. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397:710-713[CrossRef][Medline].
51. Vodovotz, Y., C. Bogdan, J. Paik, Q. W. Xie, and C. Nathan. 1993. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J. Exp. Med. 178:605-613[Abstract/Free Full Text].
52. Wahl, S. M., J. B. Allen, B. S. Weeks, H. L. Wong, and P. E. Klotman. 1993. Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. Proc. Natl. Acad. Sci. USA 90:4577-4581[Abstract/Free Full Text].
53. Wahl, S. M., I. M. Katona, B. M. Stadler, R. L. Wilder, W. E. Helsel, and L. M. Wahl. 1984. Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). II. Functional properties of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions. Cell. Immunol. 85:384-395[CrossRef][Medline].
54. Walsh, T. J., S. Aoki, F. Mechinaud, J. Bacher, J. Lee, M. Rubin, and P. A. Pizzo. 1990. Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J. Infect. Dis. 161:755-760[Medline].
55. Walsh, T. J., J. Bacher, and P. A. Pizzo. 1988. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab. Anim. Med. 38:467-471.
56. Walsh, T. J., P. O. Whitcomb, S. G. Revankar, and P. A. Pizzo. 1995. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 76:2357-2362[CrossRef][Medline].
57. Welch, G. R., H. L. Wong, and S. M. Wahl. 1990. Selective induction of Fc gamma RIII on human monocytes by transforming growth factor-beta. J. Immunol. 144:3444-3448[Abstract].
58. Williams, A. O., S. J. Chanock, and C. Flanders. 1995. TGF-beta isoforms in leprosy: immunohistochemical studies. Cell Vision 2:363-372.
59. Yang, X., J. J. Letterio, R. J. Lechleider, L. Chen, R. Hayman, H. Gu, A. B. Roberts, and C. Deng. 1999. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 18:1280-1291[CrossRef][Medline].
60. Zhang, Y., and R. Derynck. 1999. Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell Biol. 9:274-279[CrossRef][Medline].


Infection and Immunity, August 2001, p. 5115-5120, Vol. 69, No. 8
0019-9567/01/$04.00+0   DOI: 10.1128/IAI.69.8.5115-5120.2001



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Letterio, J. J.
Right arrow Articles by Chanock, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Letterio, J. J.
Right arrow Articles by Chanock, S. J.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals